Oracle Corp (NYSE:ORCL, ETR:ORC) is pushing further into the healthcare sector with a sweeping rollout of new artificial intelligence (AI) capabilities across its suite of health products — from patient portals and payer-provider tools to supply chain systems and clinical trial platforms. The move underscores how big tech is accelerating its presence in the industry, betting that AI can solve longstanding inefficiencies in how care is delivered and managed.
What Oracle has revealed
The company has disclosed a range of updates in September 2025, signalling that healthcare remains central to its enterprise growth strategy. Generative AI is at the core, used to automate routine processes, personalise patient engagement, and enhance clinical research.
Patient experience upgrades — Oracle is bringing new AI-capabilities to its patient portal. These include conversational and predictive tools for appointment scheduling, billing, and navigating medical records. The goal: reduce administrative load and improve usability for patients and clinicians alike.
Payer-provider collaboration — Oracle has rolled out features meant to accelerate claims processing and resolve discrepancies between payer and provider data. These are longstanding friction points in US healthcare, and Oracle is positioning AI as a way to reduce delays, errors, and cost.
Supply chain and operations — The company is applying AI to streamline hospital supply chains, forecast demand and identify potential shortages. Given global disruptions in recent years, these predictive analytics tools are aimed at improving resilience for organisations relying on complex logistics.
Clinical trials and drug discovery — Oracle is enhancing its electronic data capture (EDC) solutions to streamline data collection and monitoring in trials. In addition, partnerships such as with Absci and AMD aim to speed up drug discovery workflows. The combination of Oracle’s cloud infrastructure with AI tools is designed to reduce time-to-market and cost for biotech firms and pharma.
These announcements build on Oracle’s 2022 acquisition of Cerner, which cemented its healthcare presence, and reflect its strategy of embedding AI into the infrastructure of healthcare delivery. However, adoption risks remain: regulatory oversight, workflow integration, clinician acceptance and demonstrable return on investment are all hurdles.
What this means for the industry
Oracle’s push shows big tech treating healthcare not just as a vertical for healthcare IT, but as a domain for AI-driven transformation across operations, patient engagement, clinical research and supply chain. For providers, payers, and life sciences firms, this means more competition, more choice, and higher expectations for software partners. For investors, these moves underscore that Oracle is doubling down on AI as a growth lever in its healthcare business.
ASX companies to watch
In Australia, several listed companies are operating in related spaces, showing how Oracle’s global moves might intersect with local innovation and investment opportunities.
Among them, Pathkey.AI Ltd (ASX:PKY) has been attracting attention with its TrialKey platform, which applies machine learning to predict the probability of clinical trial success. Its first real-world validation this year showed predictions aligning with about 73% of outcomes across 11 programs, offering a potentially valuable tool for biotech sponsors, insurers and even investors.
Read more: Pathkey.AI validates TrialKey predictions with strong alignment to clinical outcomes
On the hardware side, BrainChip Holdings Ltd (ASX:BRN) is pursuing neuromorphic AI for low-power processing at the edge, which could have applications in medical devices, while Weebit Nano Ltd (ASX:WBT) continues to develop semiconductor memory technologies that support advanced computing. Infrastructure players are also relevant to the broader AI demand context. NEXTDC (ASX:NXT), the data-centre operator, is capturing demand from AI workloads that underpin tools like Oracle’s, while connectivity specialist Megaport Ltd (ASX:MP1) helps enable the fast, flexible networking required.
Most are at different stages of commercial maturity, but together they illustrate how AI’s advance in healthcare is mirrored by activity across Australia’s tech landscape — from predictive trial analytics to the infrastructure and components that make these systems possible.
Taking stock
Oracle’s recent announcements show AI becoming central to healthcare enterprise software, not just incremental enhancement.
The company’s challenge now is execution: proving these tools deliver in real clinical settings, overcoming regulatory and data-privacy hurdles, and making AI adoption seamless for users. For local companies, the opportunity is to differentiate through specialisation, speed, regulatory understanding, and partnerships.